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Protamine reduces bleeding complications
associated with carotid endarterectomy without
increasing the risk of stroke
David H. Stone, MD,a Brian W. Nolan, MD,a,b Andres Schanzer, MD,c Philip P. Goodney, MD,a
Robert A. Cambria, MD,d Donald S. Likosky, PhD,b Daniel B. Walsh, MD,a and
Jack L. Cronenwett, MD,a for the Vascular Study Group of Northern New England, Lebanon, NH;
Worcester, Mass; and Bangor, Me
Objectives: Controversy persists regarding the use of protamine during carotid endarterectomy (CEA) based on prior
conflicting reports documenting both reduced bleeding as well as increased stroke risk. The purpose of this study was to
determine the effect of protamine reversal of heparin anticoagulation on the outcome of CEA in a contemporary
multistate registry.
Methods:We reviewed a prospective regional registry of 4587 CEAs in 4311 patients performed by 66 surgeons from 11
centers inNorthernNewEngland from 2003-2008. Protamine use varied by surgeon (38% routine use, 44% rare use, 18%
selective use). Endpoints were postoperative bleeding requiring reoperation as well as potential thrombotic complica-
tions, including stroke, death, and myocardial infarction (MI). Predictors of endpoints were determined by multivariate
logistic regression after associated variables were identified by univariate analysis.
Results: Of the 4587 CEAs performed, 46% utilized protamine, while 54% did not. Fourteen patients (0.64%) in the
protamine-treated group required reoperation for bleeding compared with 42 patients (1.66%) in the untreated cohort
(P .001). Protamine use did not affect the rate ofMI (1.1% vs 0.91%, P .51), stroke (0.78% vs 1.15%, P .2), or death
(0.23% vs 0.32%, P .57) between treated and untreated patients, respectively. By multivariate analysis, protamine (odds
ratio [OR] 0.32, 95% confidence interval [CI], 0.17-0.63; P .001) and patch angioplasty (OR 0.46, 95%CI, 0.26-0.81;
P  .007) were independently associated with diminished reoperation for bleeding. A single center was associated with
a significantly higher rate of reoperation for bleeding (OR 6.47, 95%CI, 3.02-13.9; P< .001). Independent of protamine
use, consequences of reoperation for bleeding were significant, with a four-fold increase in MI, a seven-fold increase in
stroke, and a 30-fold increase in death.
Conclusion: Protamine reduced serious bleeding requiring reoperation during CEA without increasing the risk of MI,
stroke, or death, in this large, contemporary registry. In light of significant complications referable to bleeding, liberal use
of protamine during CEA appears warranted. (J Vasc Surg 2010;51:559-64.)Thromboembolic events are a significant cause of peri-
operative stroke during carotid endarterectomy (CEA).1 In
an attempt to minimize this and other periprocedural com-
plications, details of surgical technique have been the focus
of considerable attention.2-7 One area of continued con-
troversy is whether to reverse heparin anticoagulation with
protamine sulfate during CEA.
Protamine proponents cite the benefit of diminished
bleeding complications without increasing the risk of stroke
or other thrombotic complications.8-10 Surgeons who do
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doi:10.1016/j.jvs.2009.10.078not use protamine cite the potential for increased throm-
botic complications including stroke or myocardial infarc-
tion (MI), or anaphylactic reactions to protamine,11 with
an acceptably low incidence of bleeding complications
without using protamine.12,13
Despite substantial literature devoted to CEA, data
remain conflicted about the safety and efficacy of protamine
use. Two reports addressing the use of protamine during
CEA documented an increased association of stroke with
protamine administration.12,13 By comparison, three re-
ports document diminished bleeding associated with pro-
tamine use during CEA without an increased risk of
stroke.8-10 Differences in these studies may reflect relatively
small sample sizes from single-center experiences. Given
the low incidence of both bleeding complications and
stroke during CEA, these studies may have been under-
powered to reach definitive conclusions. The purpose of
this study was to use a large multistate registry to examine
the impact of protamine use during CEA. Specifically, we
sought to determine whether protamine had an effect on
the incidence of bleeding complications, measured as reop-
eration for bleeding, as well as an impact on the incidence of
thrombotic complications, measured as MI, stroke, and
death.
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Subjects and database. This study reflects data col-
lected in the prospectively compiled registry of the Vascular
Study Group of Northern New England (VSGNNE). This
effort represents a regional cooperative quality improve-
ment initiative started in 2003 to study vascular surgery
outcomes.14,15 Patients were treated at 11 academic and
community centers (Appendix I, online only) by 66 partic-
ipating surgeons. Trained clinical data abstractors, nurses,
and surgeons entered data prospectively for over 70 clinical,
operative, and demographic variables. All analysts were
blinded to patient, surgeon, and center identification.
All CEAs performed between 2003 and 2008 were
identified (n 4672). Combined CABG/CEA procedures
(n  85) were excluded from the analysis, resulting in a
study cohort of 4587 CEAs performed in 4311 patients.
Heparin and protamine use during surgery were at the
discretion of the operating surgeon.
Outcomes and variable definitions. The endpoints
of this study were postoperative bleeding requiring reop-
eration (to determine a potential benefit of protamine) and
postoperative MI, stroke, or death (to reflect thrombotic
complications potentially associated with protamine). Ana-
phylactic reactions to protamine were not specifically re-
corded, but mortality, length of stay, and hypotension
requiring intravenous (IV) medication at any time during
hospitalization were recorded and were analyzed as poten-
tial surrogates for other potential serious complications of
protamine administration. All endpoints were restricted to
the hospitalization for CEA. The stroke endpoint included
both major (defined as disability causing non-independent
living status) and minor (defined as non-disabling) events.
MI was defined by either troponin level or EKG changes
detected during routine clinical care.
Statistical analysis. Variables associated with end-
points were initially identified by univariate analysis of
potentially relevant variables using Pearson chi-square
(Fisher’s exact correction). Variables found to be significant
at P  .10 were then entered into a multivariate model
using backwards stepwise logistic regression. Odds ratios
(OR) and 95% confidence intervals (CI) were generated for
significant endpoint predictors.
To further investigate outcomes of our multivariate
model, surgeon-specific cluster analysis was performed.
Protamine use, stroke, and cranial nerve injury were strati-
fied by both low and high rates of surgeon-associated
reoperation for bleeding. Crainial nerve injury was selected
as a proxy measure of a less “technically careful” surgeon to
better identify whether these surgeons accounted for in-
creased reoperation for bleeding. The study was conducted
in compliance with the Institutional Review Board at Dart-
mouth Medical School.
RESULTS
During the 4587 CEAs performed, 46% (n 2087) of
the patients received intraoperative protamine while 54%
(n  2500) did not. Most procedures were performedelectively, using general anesthesia, patch angioplasty, and
intraoperative shunting. The majority of patients in both
the protamine-treated and untreated groups were taking
antiplatelet therapy (90% vs 87%, P  NS) at the time of
CEA. Additional demographic details, comorbidities, and
preoperative medications of the study cohort are depicted
in Table I.
Protamine use varied by surgeon. When stratified by
frequency of use, 38% (n 25) of surgeons used protamine
routinely (defined as during more than 80% of their CEAs),
44% (n  29) used it rarely (defined as 10% of their
CEAs), and 18% (n  12) used protamine selectively dur-
ing surgery (defined as use between 10% and 80% of CEAs
performed. These cutpoints were chosen to best separate
the three groups based on inspection of the distribution.
Reoperation for bleeding was performed in 1.66% (n
42) of patients who did not receive protamine compared
with 0.64% (n  14) of those who did (Fig 1). Clinical
predictors that showed univariate association with dimin-
ished bleeding requiring reoperation (at P .10) included
intraoperative protamine use, intraoperative shunting,
patch angioplasty, and general anesthesia. A history of renal
insufficiency (Cr1.8 mg/dL) and baseline low hemoglo-
bin (defined as 9 gm/dL) were univariately associated
with increased bleeding requiring reoperation. Four spe-
cific centers also demonstrated a univariate association with
reoperation for bleeding. The complete univariate analysis
is available as Appendix II (online only).
Multivariate logistic regression confirmed that prota-
mine administration was an independent predictor of di-
minished reoperation for bleeding, after accounting for
Table I. Demographic variables, comorbidities, and
preoperative medications of protamine-treated and
untreated patients
Protamine Yes (%) No (%) P value
Age (years) 69.2 70.0 NS
Gender (male) 60 60 NS
DM 33 30 .03
HTN 87 86 NS
CAD 36 32 .01
CHF 9 7 .005
Smoking 81 80 NS
COPD 25 22 .02
Creatinine  1.8 7 6 .1
Aspirin 87 82 .02
Plavix 21 13 .0001
Anti-platelet 90 87 NS
Statin 72 69 .07
-blocker 83 85 NS
Elective 93 88 .0001
Any preoperative symptoms 34 38 .01
Ipsilateral preoperative symptoms 25 27 .1
Patch 91 76 .0001
General anesthesia 48 52 .001
CAD, Coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease;DM, diabetes mellitus;HTN, hyper-
tension.other variables, including center variation, surgical tech-
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addition, patch angioplasty demonstrated a significant as-
sociation with diminished reoperation for bleeding (OR
0.46, P  .007), while a single center, with a protamine
utilization rate of 63%, was associated with an increased
incidence of reoperation for bleeding (OR 6.47, P .001;
95% CI are listed in Table II).
The above observation that both protamine and patch-
ing reduced bleeding led to the question of whether these
variables might be a proxy for more careful or expert
surgeons. This led to further surgeon-specific cluster anal-
ysis (Table III).When stratified by either a low rate (0%-3%)
of reoperation for bleeding versus a high rate (5%-12%) of
reoperation for bleeding, there were no significant differ-
ences in the incidence of either transient cranial nerve injury
(5.7% vs 4.8%) or stroke (0.9% vs 1.4%).
Thrombotic complications were not significantly af-
Fig 1. Reoperation for bleeding. Reoperation for bleeding was
reduced three-fold in patients receiving protamine.
Table II. Significant independent predictors associated
with reoperation for bleeding
Odds ratio
95% CI for OR
P valueLower Upper
Protamine 0.32 0.17 0.63 .001
Patch 0.46 0.26 0.81 .007
One center 6.47 3.02 13.9 .001
CI, Confidence interval; OR, odds ratio.
Table III. Surgeon-specific sub-analyses comparing the
incidence of stroke and cranial nerve injury stratified by
surgeons with low and high rates of reoperation for
bleeding
Reoperation for bleeding Stroke Cranial nerve injury
Low rate (0%-3%) 0.9% 5.7%
High rate (5%-12%) 1.4% 4.8%fected by protamine administration. There were no signif-icant differences in the incidence of stroke, death, or clini-
cally apparent MI among patients who received protamine
versus those who did not (Fig 2). Regardless of protamine
treatment, however, the observed consequences of reop-
eration for bleeding were significant. There was an ob-
served increase in the incidence of clinically significant MI
among patients requiring reoperation compared with those
patients who did not (3.6% vs 0.9%, P  .05). In addition,
the incidence of stroke was greater among patients who
required reoperation for bleeding (7.1% vs 0.9%, P .001).
Lastly, the incidence of in-hospital death among patients
who required re-exploration for bleeding was notably
higher compared with patients who did not require reop-
eration for bleeding (7.1% vs 0.19%, P  .001; Fig 3).
In order to identify any other potential complications
of protamine use, several additional variables were exam-
ined. Protamine use was associated with a slightly higher
risk of hypotension requiring IV medication by univariate
analysis (11.8% vs 9.0%; P  .008). However, this associa-
tion was not significant in our multivariate model when
adjusted for potentially confounding variables (OR 0.92;
95% CI, 0.7-1.2; P  .53). Observed length of stay was
over two-fold greater among patients who underwent re-
operation for bleeding versus those who did not (2.0 vs 4.6
Fig 2. Thrombotic complications. There were no observed sig-
nificant differences in the incidence of major thrombotic compli-
cations, including MI, stroke, and death between protamine-
treated and untreated patients.
Fig 3. Consequences of reoperation for bleeding. Regardless of
protamine use, the consequences of reoperation for bleeding were
significant. Patients who required reoperation for bleeding had a
significantly higher risk of MI, stroke, and death, compared with
patients without this bleeding complication.days, P  .001).
ial inf
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increased incidence of MI, stroke, or death, which could
also represent surrogate endpoints for adverse protamine
reactions. Consistent with this finding, there was no ob-
served difference in the incidence of combined MI, stroke,
and death among insulin-dependent diabetic patients who
received protamine versus those who did not (4.8% vs 2.
8%, P  .3).
DISCUSSION
This study is among the first to definitively demonstrate
that protamine was associated with diminished reoperation
for bleeding during CEA in a large prospective registry,
without an observed increase in associated thrombotic
complications, including MI, stroke, or death. Further-
more, the present study demonstrates a nearly three-fold
increased rate of serious bleeding requiring reoperation
among those who do not receive protamine during CEA.
As noted, controversy persists regarding the use of
protamine during CEA. Previous studies on this topic are
summarized in Table IV. There has been only a single
randomized trial that has addressed whether protamine
administration is safe during CEA.12 In this study, 64
patients were randomized to undergo reversal of heparin
anticoagulation versus no pharmacologic treatment. A total
of 31 patients received intraoperative protamine and sub-
sequently had diminished wound drainage with no impact
on neck swelling compared with the untreated cohort.
Perhaps more striking, however, was the finding that two
protamine-treated patients acutely thrombosed their re-
spective operated internal carotid arteries and died. Based
Table IV. Studies examining the use of protamine during
Author Year Treated patients (N) Bl
Treiman et al.10 1990 328 Increa
untr
1.8%
Mauney et al.13 1995 348 No eff
hem
P 
Fearn et al.12 1997 64 Decrea
with
35 m
chan
Levison et al.9 1999 407 Decrea
with
9.5%
Dellagrammaticas et al.8 2008 594 Decrea
with
10.4
diffe
with
3.2%
Stone et al. 2009 2087 Decrea
blee
(0.6
CVA, Cerebral vascular accident; ICA, internal carotid artery; MI, myocardon these findings, the authors concluded that protamineuse may predispose to internal carotid artery (ICA) throm-
bosis and subsequent stroke. This study, however, con-
sisted of only 64 patients, making it difficult to extrapolate
definitive conclusions regarding protamine use.12
By comparison, a post-hoc analysis from the GALA trial
(General Anesthetic Versus Local Anesthetic for Carotid
Surgery Trial) examined outcomes of patients treated with
protamine versus those who were untreated.8 Specifically,
the authors documented a 4.4% stroke rate among un-
treated patients versus 2.9% among protamine-treated pa-
tients (P  .098). Furthermore, the study demonstrated a
statistically lower incidence of associated neck hematoma in
the protamine-treated group compared with the untreated
cohort (7.4% vs 10.4%; P  .037). The authors concluded
that their findings refute the perception that protamine is
associated with deleterious outcomes during CEA.
The above finding of diminished neck hematomas
among treated patients in the GALA trial and the observed
diminished incidence of reoperation for bleeding in our
study have significant clinical implications. Historically,
many surgeons have advocated CEA using aggressive anti-
coagulation with a tacit willingness to accept an increased
associated incidence of bleeding complications.16,17 In-
deed, LaMuraglia et al, among others, note that significant
hematomas were the most common complication observed
in their CEA experience, although only a minority of
patients required reoperation for bleeding.16 Our study
demonstrates that the sequelae of reoperation for bleeding
were significant. Indeed, patients requiring reoperation for
bleeding demonstrated an increased incidence of MI,
stroke, and death, although the cause for this observation
tid endarterectomy to date
g complications Thrombotic complications
ound hematoma in
patients (6.5% vs
.004)
No effect on CVA (1.8% vs 2.7%, P  .6)
significant
a (1.0% vs 1.9%,
Increased CVA with protamine (2.6% vs
0%, P  .05)
ound drainage
amine (69 mL, vs
 .001); no
neck swelling
Increased CVA with protamine (3 patients
with ICA thrombosis)
ound hematoma
amine (1.9% vs
.02)
Increased CVA with protamine (2.7% vs
0%, P  .33)
ound hematoma
amine (7.4% vs
 .04); no
in reoperation
amine (3.7% vs
.58)
No effect on CVA (4.4% vs 2.9%, P  .1)
eoperation for
with protamine
1.66%, P  .001)
No effect on CVA (0.78% vs 1.15%, P 
.2) No effect on MI (1.1% vs 0.91%,
P  .51) No effect on death (0.23% vs
0.32%, P  .57)
arction.caro
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4% vsremains undefined. Return to the operating room with its
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iologic impact on cardiac physiology, perhaps partly ac-
counting for the observed increased incidence in MI, al-
though this remains speculative. An increased incidence in
stroke upon return to the operating room may reflect the
need for reclamping and/or operative revision with its
inherent transient cerebral ischemia; however, the timing of
these associated neurologic events is not recorded in this
dataset, thereby limiting our conclusions regarding this
association. Furthermore, the observed increase in death
may reflect a myriad of etiologies including a second anes-
thetic, potential reclamping, and ongoing bleeding in a
high-risk patient cohort. These findings highlight the im-
portance of adequate hemostasis and we believe justify a
more liberal stance toward intraoperative heparin reversal
during CEA. Although protamine did not decrease the
incidence of MI, stroke, or death by multivariate analysis,
our study was not powered to detect such an effect, given
the multiple clinical causes of these more severe endpoints.
However, diminished reoperation for bleeding was signifi-
cantly associated with protamine use, so by extrapolation, a
beneficial effect on more severe complications related to
reoperation is likely. A novel observation made by our
multivariate analysis was that patch angioplasty, utilized in
91% and 76% of the treated and untreated patients, in
addition to protamine, was independently associated with
diminished reoperation for bleeding. To better account for
this observation, surgeon-specific analyses were performed
to assess whether patch angioplasty served as a proxy mea-
sure for a “careful,” technically expert surgeon. When
surgeon-associated reoperation for bleeding rates were sub-
divided into both low rates (0%-3%) and high rates (5%-
12%), there was no observed statistical correlation with
transient cranial nerve injury or stroke rate. This finding
suggests that patch angioplasty is not likely a proxy for the
more “careful” surgeon, although the explanation for a
beneficial effect of patching is not clear and requires further
study.
Previous reports have documented the potential for
hypotension to be associated with protamine use.18-21 It
remains difficult to draw definitive conclusions regarding
protamine and hypotension requiring IV medication, since
blood pressure thresholds warranting therapy remained at
the discretion of the attending physicians. Multivariate
analysis, however, indicated that protamine was not associ-
ated with increased hypotension requiring treatment, and
more severe sequelae of hypotension, such as MI, were not
increased by protamine use.
This study has several limitations. First, it does not
provide Level I evidence of a randomized controlled trial.
However, it was adequately powered to detect a difference
in low frequency complications in a “real world” practice
experience that reflects both academic and community
practices. Second, the dosing of protamine and heparin
was not standardized, which could potentially confound
outcomes. As noted by Levison et al, excessive prota-
mine dosing may paradoxically lead to increased bleeding/
hematoma formation.9 In addition, 90% of patients receiv-ing protamine were on antiplatelet therapy at the time of
surgery, which could potentially reduce the incidence of
observed thrombotic complications among patients receiv-
ing protamine. In addition, the VSGNNE registry does not
record data regarding anaphylactic reactions to protamine.
Although other reports have documented the incidence of
significant anaphylactic protamine reactions to be quite low
(0.19%-0.69%), we could only infer that this complication
was rare, since it did not detract from the observed benefi-
cial results of protamine treatment.11 Finally, recor-
ded strokes in this study were not neurologist-adjudicated as
they were in the GALA trial report by Dellagrammaticas et
al.8 However, both studies demonstrate similar conclusions
that protamine is not statistically associated with increased
stroke rates. Despite these limitations, this study reports
real practice outcomes among surgeons who by chance
were nearly evenly split in their use of protamine, thereby
approximating a random comparison, since our analysis
demonstrated that the benefit of protamine persisted when
controlled for individual surgeon or center effects.
CONCLUSIONS
Based on the analysis of nearly 5,000 patients, this
study demonstrates that protamine is associated with sig-
nificantly diminished reoperation for bleeding during CEA,
without increasing thrombotic risk, as practiced in a large
regional registry, reflecting both academic and community
practices. Currently, further analysis is underway to exam-
ine details of heparin and protamine dosing, but in the
interim, these data support the use of protamine during
carotid endarterectomy, given the major consequences of
reoperation for bleeding.
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Volume 51, Number 3 Stone et al 564.e1Appendix: I, online only. Participating centers of the
Vascular Study Group of Northern New England
Center Location
Catholic Medical Center Manchester, NH
Central Maine Medical Center Lewiston, Me
Concord Hospital Concord, NH
Cottage Hospital Woodsville, NH
Dartmouth-Hitchcock Medical Center Lebanon, NH
Eastern Maine Medical Center Bangor, Me
Fletcher Allen Health Care Burlington, Vt
Lakes Region General Hospital Laconia, NH
Maine Medical Center Portland, Me
Mercy Hospital Portland, Me
UMASS Memorial Medical Center Worcester, MassAppendix II, online only. Univariate predictors
associated with reoperation for bleeding
Reoperation for
bleeding if
present
Reoperation for
bleeding if not
present P value
Center 2 1.9 0.9 .004
CHF 2.0 1.1 .1
Cr1.8 2.2 1.1 .09
Center 8 4.8 1.0 .001
Low Hb (9) 6.3 1.2 .06
Center 9 0.0 1.3 .01
Center 10 0.6 1.3 .1
Protamine 0.6 1.6 .001
Shunt 0.8 1.5 .02
Patch 0.9 2.5 .001
Statin 1.0 1.5 .10
GETA 1.0 2.2 .03anesthesia; Hb, hemoglobin.
